StockData
Galectin Therapeutics Inc logo

Galectin Therapeutics Inc (GALT) stock

GALTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 0/30
$2.98+0.07 (+2.41%)

Close on Nov 18, 2026Market cap $300.53MP/E –Yield –

Galectin Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

No revenue figures for Galectin Therapeutics

Galectin Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Galectin Therapeutics figures

See a number that looks wrong?